EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CRISPR-Cas9 high-throughput screening to study drug resistance in Leishmania infantum

Marine Queffeulou iD, Philippe Leprohon, Christopher Fernandez-Prada, Marc Ouellette iD, Ana María Mejía-Jaramillo iD

mBio · 17.07.2024 · 15 (7)

DOI: 10.1128/mbio.00477-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mBio, erschienen am 17.07.2024. Verfasst von Marine Queffeulou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Centre de Recherche en Infectiologie du Centre de Recherche du CHU Québec, Université Laval, Québec, Canada. Hauptthemen laut MEDLINE: Leishmania infantum, CRISPR-Cas Systems, Drug Resistance, Antiprotozoal Agents. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Government | Canadian Institutes of Health Research (CIHR), Syndicat des Professeurs et Professeures de l'Universite Laval Leadership fellowship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Parasites of the genus Leishmania pose a global health threat with limited treatment options. New drugs are urgently needed, and genomic screens have the potential to accelerate target discovery, mode of action, and resistance mechanisms against these new drugs. We describe here our effort in developing a genome-wide CRISPR-Cas9 screen in Leishmania , an organism lacking a functional nonhomologous end joining system that must rely on microhomology-mediated end joining, single-strand annealing, or homologous recombination for repairing Cas9-induced double-stranded DNA breaks. A new vector for cloning and expressing single guide RNAs (sgRNAs) was designed and proven to be effective in a small pilot project while enriching specific sgRNAs during drug selection. We then developed a whole-genome library of 49,754 sgRNAs, targeting all the genes of Leishmania infantum . This library was transfected in L. infantum expressing Cas9, and these cells were selected for resistance to two antileishmanials, miltefosine and amphotericin B. The sgRNAs the most enriched in the miltefosine screen targeted the miltefosine transporter gene, but sgRNAs targeting genes coding for a RING-variant protein and a transmembrane protein were also enriched. The sgRNAs the most enriched by amphotericin B targeted the sterol 24 C methyltransferase genes and a hypothetical gene. Through gene disruption experiments, we proved that loss of function of these genes was associated with resistance. This study describes the feasibility of carrying out whole-genome CRISPR-Cas9 screens in Leishmania provided that a strong selective pressure is applied. Such a screen can be used for accelerating the development of urgently needed antileishmanial drugs. IMPORTANCE Leishmaniasis, a global health threat, lacks adequate treatment options and drug resistance exacerbates the challenge. This study introduces a CRISPR-Cas9 screening approach in Leishmania infantum , unraveling mechanisms of drug resistance at a genome-wide scale. Our screen was applied against two main antileishmanial drugs, and guides were enriched upon drug selection. These guides targeted known and new targets, hence validating the use of this screen against Leishmania . This strategy provides a powerful tool to expedite drug discovery as well as potential therapeutic targets against this neglected tropical disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leishmania infantumCRISPR-Cas SystemsDrug ResistanceAntiprotozoal AgentsHigh-Throughput Screening AssaysPhosphorylcholineAmphotericin BRNA, Guide, CRISPR-Cas SystemsGenome, Protozoan

Stichwörter der Autor:innen

CRISPR-Cas9Leishmaniaamphotericin Bdrug resistancemiltefosinenext-generation sequencing

Substanzen

Antiprotozoal AgentsPhosphorylcholinemiltefosineAmphotericin BRNA, Guide, CRISPR-Cas Systems

Autor:innen und Institutionen

  • Centre de Recherche en Infectiologie du Centre de Recherche du CHU Québec, Université Laval, Québec, Canada.
  • Département de Microbiologie, Infectiologie et Immunologie, Faculté de Médecine, Université Laval, Québec, Canada.

ORCID-Profile: Marine Queffeulou, Marc Ouellette, Ana María Mejía-Jaramillo

Förderung

  • Canadian Government | Canadian Institutes of Health Research (CIHR)
  • Syndicat des Professeurs et Professeures de l'Universite Laval Leadership fellowship

Zitieren

APA

Queffeulou, M., Leprohon, P., Fernandez-Prada, C., Ouellette, M., & Mejía-Jaramillo, A. M. (2024). CRISPR-Cas9 high-throughput screening to study drug resistance in Leishmania infantum. mBio, 15(7). https://doi.org/10.1128/mbio.00477-24

Vancouver

Queffeulou M, Leprohon P, Fernandez-Prada C, Ouellette M, Mejía-Jaramillo AM. CRISPR-Cas9 high-throughput screening to study drug resistance in Leishmania infantum. mBio. 2024;15(7). doi:10.1128/mbio.00477-24

BibTeX
@article{Queffeulou2024,
  author = {Queffeulou, Marine and Leprohon, Philippe and Fernandez-Prada, Christopher and Ouellette, Marc and Mejía-Jaramillo, Ana María},
  title = {CRISPR-Cas9 high-throughput screening to study drug resistance in Leishmania infantum},
  journal = {mBio},
  year = {2024},
  volume = {15},
  number = {7},
  doi = {10.1128/mbio.00477-24}
}
Kostenlos starten →